Novartis, Astellas, GSK Ads Misbranded Drugs: FDA
The FDA publicized the letters that it sent to alert the pharmaceutical companies that they had misbranded their drugs in violation of the Federal Food, Drug and Cosmetic Act.
GSK's alleged misbranding relates to Arzerra, which is used to treat lymphocytic leukemia. The FDA objects to a Dec. 1 ad in the Journal...
To view the full article, register now.